CA3087261A1 - Benzamide compounds - Google Patents

Benzamide compounds Download PDF

Info

Publication number
CA3087261A1
CA3087261A1 CA3087261A CA3087261A CA3087261A1 CA 3087261 A1 CA3087261 A1 CA 3087261A1 CA 3087261 A CA3087261 A CA 3087261A CA 3087261 A CA3087261 A CA 3087261A CA 3087261 A1 CA3087261 A1 CA 3087261A1
Authority
CA
Canada
Prior art keywords
cancer
unsubstituted
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087261A
Other languages
English (en)
French (fr)
Inventor
Joseph Robert Pinchman
Peter Qinhua HUANG
Kevin Duane Bunker
Rakesh Kumar Sit
Ahmed Abdi Samatar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of CA3087261A1 publication Critical patent/CA3087261A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/38—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
    • C07C47/42—Unsaturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings with a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/517—Saturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Cephalosporin Compounds (AREA)
CA3087261A 2018-01-10 2019-01-08 Benzamide compounds Pending CA3087261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615857P 2018-01-10 2018-01-10
US62/615,857 2018-01-10
PCT/US2019/012695 WO2019139899A1 (en) 2018-01-10 2019-01-08 Benzamide compounds

Publications (1)

Publication Number Publication Date
CA3087261A1 true CA3087261A1 (en) 2019-07-18

Family

ID=67218673

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3087261A Pending CA3087261A1 (en) 2018-01-10 2019-01-08 Benzamide compounds
CA3087262A Pending CA3087262A1 (en) 2018-01-10 2019-01-08 Benzamide compounds
CA3087263A Pending CA3087263A1 (en) 2018-01-10 2019-01-08 Benzamide compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3087262A Pending CA3087262A1 (en) 2018-01-10 2019-01-08 Benzamide compounds
CA3087263A Pending CA3087263A1 (en) 2018-01-10 2019-01-08 Benzamide compounds

Country Status (16)

Country Link
US (7) USRE50643E1 (enExample)
EP (4) EP4556469A1 (enExample)
JP (4) JP2021510165A (enExample)
KR (4) KR20200108301A (enExample)
CN (5) CN118084904A (enExample)
AR (4) AR114998A1 (enExample)
AU (4) AU2019207611A1 (enExample)
BR (3) BR112020014169A2 (enExample)
CA (3) CA3087261A1 (enExample)
ES (1) ES3013457T3 (enExample)
IL (4) IL275762B2 (enExample)
MX (4) MX2020007014A (enExample)
RU (2) RU2020120929A (enExample)
SG (3) SG11202005785XA (enExample)
TW (5) TW201930317A (enExample)
WO (4) WO2019139902A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
EP3612531B1 (en) 2017-04-18 2022-08-24 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
KR20220034038A (ko) * 2019-07-10 2022-03-17 리커리엄 아이피 홀딩스, 엘엘씨 Bcl-2 억제제의 나노입자 제형
AU2020310147A1 (en) * 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
AU2020407070A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
IL294067A (en) * 2019-12-20 2022-08-01 Recurium Ip Holdings Llc Combinations
AU2020404996A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
US20230065577A1 (en) * 2019-12-20 2023-03-02 Recurium Ip Holdings, Llc Combinations
WO2021167987A1 (en) 2020-02-21 2021-08-26 Recurium Ip Holdings, Llc Difluoromethyl iodo compounds and methods
US20230167105A1 (en) * 2020-04-28 2023-06-01 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2023525022A (ja) * 2020-05-07 2023-06-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
BR112022023486A2 (pt) * 2020-05-19 2023-01-10 Recurium Ip Holdings Llc Tratamento para amiloidose
BR112023000320A2 (pt) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
US20230381172A1 (en) * 2020-10-16 2023-11-30 Recurium Ip Holdings, Llc Combinations of bcl-2 inhibitors with chemotherapeutic agents
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途
CN113816889B (zh) * 2021-10-11 2023-08-22 中国药科大学 一类4-磺酰亚胺-1H-吡咯类Mcl-1抑制剂及其抗肿瘤医药用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
JP2003096461A (ja) 2001-09-25 2003-04-03 Fuji Photo Film Co Ltd 液晶組成物およびそれを用いた液晶素子
DE10217814A1 (de) 2002-04-22 2003-11-13 Ibfb Pharma Gmbh Neue tricyclische Mercaptane, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
JP4628140B2 (ja) 2005-03-03 2011-02-09 富士フイルム株式会社 セルロースアシレートフィルム、偏光板および液晶表示装置
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US20100234364A1 (en) 2006-07-14 2010-09-16 Arindrajit Basak Ccr2 inhibitors and methods of use thereof
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
EP2094672B1 (en) 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20080199873A1 (en) * 2006-12-04 2008-08-21 Anderson Mark G Companion diagnostic assays for cancer therapy
WO2009036051A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2376480T3 (en) * 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010083442A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
KR20120052937A (ko) 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
WO2010148422A1 (en) 2009-06-25 2010-12-29 Walter And Eliza Hall Institute Of Medical Research Compounds and methods for treating parasitic infestations
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG190204A1 (en) 2010-11-11 2013-06-28 Redx Pharma Ltd Drug derivatives
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
EP2668180B1 (en) 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
FR2986002B1 (fr) 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2013185202A1 (en) 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
EP3689886A1 (en) 2013-01-16 2020-08-05 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
CN105164128B (zh) 2013-03-13 2017-12-12 艾伯维公司 制备细胞凋亡诱导剂的方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2999470B1 (en) 2013-05-22 2017-08-16 Children's Hospital Medical Center Combination therapy for mds
AU2014269144B2 (en) 2013-05-24 2019-10-31 Mark Barry HAMPTON Bioactive compounds
CN105793424B (zh) 2013-07-12 2021-02-19 亥姆霍兹感染研究中心有限公司 孢囊菌酰胺
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
CN105012318B (zh) 2014-04-17 2020-02-11 沈华浩 磺酰胺类化合物在气道慢性炎症性疾病中的应用
CN104131034B (zh) 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
WO2016025652A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a bcl-2 pathway modulator and related methods
US10308609B2 (en) * 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
WO2016127135A1 (en) 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
WO2016131100A1 (en) 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
EP4461314A3 (en) 2015-04-20 2024-12-11 Mayo Foundation for Medical Education and Research Methods and materials for killing hiv infected cells
PE20180454A1 (es) 2015-05-26 2018-03-05 Hoffmann La Roche Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2
GB201513481D0 (en) 2015-07-30 2015-09-16 Univ Manchester Inhibitor compounds
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN106608895A (zh) 2015-10-21 2017-05-03 苏州国匡医药科技有限公司 一类具有糖环结构的bcl-2选择性抑制剂及其用途
WO2017101851A1 (en) 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
CN106957315B (zh) 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
JP2019501225A (ja) 2016-01-11 2019-01-17 メリマック ファーマシューティカルズ インコーポレーティッド Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CA3026651A1 (en) 2016-06-09 2017-12-14 Blinkbio, Inc. Silanol based therapeutic payloads
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106565607B (zh) 2016-10-11 2019-03-26 湖北泓肽生物科技有限公司 一种l-肌肽的合成方法
CN106565706B (zh) 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
CN106749233B (zh) 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
KR20200108301A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
SG11202009933WA (en) 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
SG11202101955SA (en) 2018-09-18 2021-03-30 Signalchem Lifesciences Corp Combination therapy for treating blood cancer

Also Published As

Publication number Publication date
KR102751751B1 (ko) 2025-01-10
US11344546B2 (en) 2022-05-31
TW201934550A (zh) 2019-09-01
TW201934538A (zh) 2019-09-01
AR114948A1 (es) 2020-11-11
KR20250008139A (ko) 2025-01-14
AU2019207611A1 (en) 2020-07-09
TW202417442A (zh) 2024-05-01
US20210009543A1 (en) 2021-01-14
CA3087262A1 (en) 2019-07-18
AU2019207616A1 (en) 2020-07-09
MX2020007388A (es) 2020-10-12
KR20200108298A (ko) 2020-09-17
RU2020120928A (ru) 2022-02-25
EP3737672A4 (en) 2021-09-15
US20240180899A1 (en) 2024-06-06
IL275762B1 (en) 2024-12-01
CN111801320A (zh) 2020-10-20
EP3737672A1 (en) 2020-11-18
MX2023009185A (es) 2023-08-21
IL275763A (en) 2020-08-31
MX2020007014A (es) 2020-11-11
AU2019207608B2 (en) 2024-03-28
AR114998A1 (es) 2020-11-18
RU2020120929A (ru) 2022-02-25
JP2021510163A (ja) 2021-04-15
CN118084904A (zh) 2024-05-28
EP3740487A1 (en) 2020-11-25
US11813259B2 (en) 2023-11-14
US11590126B2 (en) 2023-02-28
SG11202005985PA (en) 2020-07-29
BR112020014151A2 (pt) 2020-12-08
TW201930317A (zh) 2019-08-01
KR20200108302A (ko) 2020-09-17
TWI829664B (zh) 2024-01-21
EP3740487B1 (en) 2025-01-08
US11318134B2 (en) 2022-05-03
JP2024001052A (ja) 2024-01-09
JP2021510165A (ja) 2021-04-15
WO2019139907A1 (en) 2019-07-18
BR112020014169A2 (pt) 2020-12-08
SG11202005784YA (en) 2020-07-29
ES3013457T3 (en) 2025-04-14
CN118084905A (zh) 2024-05-28
TW201930302A (zh) 2019-08-01
NZ765825A (en) 2023-12-22
AU2024203833A1 (en) 2024-06-27
JP7355741B2 (ja) 2023-10-03
EP3740487A4 (en) 2021-11-10
EP3737681A4 (en) 2022-01-12
US20200338071A1 (en) 2020-10-29
WO2019139900A1 (en) 2019-07-18
IL316472A (en) 2024-12-01
BR112020014160A2 (pt) 2020-12-08
IL275762A (en) 2020-08-31
EP3737681A1 (en) 2020-11-18
AR114950A1 (es) 2020-11-11
IL275761A (en) 2020-08-31
KR20200108301A (ko) 2020-09-17
EP4556469A1 (en) 2025-05-21
WO2019139899A8 (en) 2020-07-16
US11813260B1 (en) 2023-11-14
US20220226314A1 (en) 2022-07-21
WO2019139902A1 (en) 2019-07-18
IL275762B2 (en) 2025-04-01
AR114949A1 (es) 2020-11-11
WO2019139899A1 (en) 2019-07-18
CN111801327B (zh) 2024-02-09
RU2020120933A (ru) 2022-02-10
SG11202005785XA (en) 2020-07-29
USRE50643E1 (en) 2025-10-21
AU2019207608A1 (en) 2020-07-09
EP3740487C0 (en) 2025-01-08
CA3087263A1 (en) 2019-07-18
CN111788203A (zh) 2020-10-16
CN111801327A (zh) 2020-10-20
JP2021510376A (ja) 2021-04-22
US20200339605A1 (en) 2020-10-29
MX2020007392A (es) 2020-10-14

Similar Documents

Publication Publication Date Title
US11813260B1 (en) Benzamide compounds
CA3138284A1 (en) Nanoparticle formulation of bcl-2 inhibitor
RU2801647C2 (ru) Бензамидные соединения
HK40040853B (en) Benzamide compounds as bci inhibitors for the treatment of hiv
HK40040853A (en) Benzamide compounds as bci inhibitors for the treatment of hiv

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240104

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241211

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250610

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251215

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260303